Attento (olmesartan medoxomil) coated tablets 40 mg/10 mg. №28

active ingredients: olmesartan medoxomil; amlodipine besilate;

Attento®40/10:

1 tablet contains olmesartan medoxomil 40 mg and amlodipine besylate 13.888 mg (equivalent to amlodipine 10 mg);

other components:

pregelatinized starch (corn), siliconized microcrystalline cellulose (contains 98% microcrystalline cellulose (Ph.Eur.) and 2% anhydrous colloidal silicon dioxide (Ph.Eur.)), croscarmellose sodium, magnesium stearate;

film sheath:

Attento® 40/10:

Oradry II 85F25467 red (polyvinyl alcohol, titanium dioxide (E 171), iron oxide yellow (E 172), iron oxide red (E 172), polyethylene glycol, talc).

Film-coated tablets.

Basic physical and chemical properties:

Attento®40/10: brownish-red round film-coated tablets, embossed “C77” on one side.

Angiotensin II antagonists and calcium channel blockers.

ATX code C09D B02.

Attento is a combination drug containing olmesartan medoxomil, an angiotensin II receptor antagonist, and amlodipine besylate, a calcium channel blocker. The combination of these two active substances has a synergistic effect and contributes to lower blood pressure to a greater extent than either active substance alone.

In an 8-week, double-blind, randomized, placebo-controlled factorial study in 1940 patients (71% Caucasian and 29% non-racial), treatment with Attento was shown to result in a significantly greater reduction in systolic blood pressure. compared with monotherapy with suitable components. The mean decrease in systolic/diastolic pressure was dose dependent: 24/14 mm Hg. Art. (20 mg/5 mg), 25/16 mmHg Art. (40 mg/5 mg) and 30/19 mm Hg. Art. (40 mg/10 mg).

Attento 40/5 reduced systolic/diastolic pressure in the sitting position by an additional 2.5/1.7 mm Hg. Art. compared to Attento 20/5. Similarly, Attento 40/10 reduced systolic/diastolic pressure in the sitting position by an additional 4.7/3.5 mmHg. Art. compared to Attento 40/5.

The proportion of patients who managed to achieve the target blood pressure values ​​(<140/90 mmHg in non-diabetic patients and <130/80 mmHg in diabetics) was 42.5%. , 51.0% and 49.1% for Attento 20/5, Attento 40/5 and Attento 40/10, respectively.

The main hypotensive effect of Attento, as a rule, was achieved within the first 2 weeks of therapy.

A second double-blind, randomized, placebo-controlled study examined the efficacy of adding amlodipine to a treatment regimen in Caucasian patients with poor response to olmesartan medoxomil monotherapy at a dose of 20 mg for 8 weeks.

In patients who continued to receive only olmesartan medoxomil 20 mg, systolic / diastolic pressure decreased by 10.6 / 7.8 mm Hg. Art. over the next 8 weeks. With the addition of 5 mg of amlodipine for 8 weeks, it was possible to achieve a decrease in systolic / diastolic pressure by 16.2 / 10.6 mm Hg. Art. (p=0.0006).

The proportion of patients who achieved target blood pressure values ​​(<140/90 mmHg in non-diabetic patients and <130/80 mmHg in diabetics) was 44.5%. for Attento 20/5 compared to 28.5% for olmesartan medoxomil 20 mg.

In the course of further studies, the effectiveness of adding various doses of olmesartan medoxomil to the treatment regimen of Caucasian patients with insufficient body response to amlodipine monotherapy at a dose of 5 mg for 8 weeks was evaluated.

In patients continuing to receive only 5 mg of amlodipine, systolic / diastolic pressure decreased by 9.9 / 5.7 mm Hg. Art. over the next 8 weeks. The addition of 20 mg of olmesartan medoxomil resulted in a decrease in systolic/diastolic blood pressure by 15.3/9.3 mm Hg. Art., the addition of 40 mg of olmesartan medoxomil – by 16.7 / 9.5 mm Hg. Art. (p<0.0001).